ProCE Banner Activity

Anti-TIGIT Therapy: Current Evidence and Key Ongoing Trials

Clinical Thought
In this commentary, Ani Balmanoukian, MD, and Jyoti D. Patel, MD, discuss emerging data with and the potential role of anti-TIGIT therapy in lung cancer and other solid tumors.

Released: May 03, 2022

Expiration: May 02, 2023

No longer available for credit.

Share

Faculty

Ani Balmanoukian

Ani Balmanoukian, MD

Director of Thoracic Oncology
Medical Oncology
The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California

Jyoti D. Patel

Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Ani Balmanoukian, MD

Director of Thoracic Oncology
Medical Oncology
The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate
Los Angeles, California

Ani Balmanoukian, MD, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, and Genentech.

Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Jyoti D. Patel, MD, has disclosed that she has received funds for research support from AstraZeneca and consulting fees from AbbVie and Takeda.